Gilead Sciences, a biopharmaceutical company in the US, on
Wednesday, announced “positive data” in the clinical trial of remdesivir, an
experimental antiviral drug, for the treatment of COVID-19.
Remdesivir was originally developed by the company as a
potential treatment for Ebola, but it failed.
According to the company, the drug was found to be effective
on COVID-19 patients during the trial which began in February.
Gilead Sciences said it administered the drug on 397
severely ill COVID-19 patients and more than half of them were discharged
within two weeks.
Aruna Subramanian, a Stanford University infectious diseases
professor who led the study, said the patients showed improvement after the
treatment.
“These data are encouraging as they indicate that patients
who received a shorter, 5-day course of remdesivir experienced similar clinical
improvement as patients who received a 10-day treatment course,” Subramanian
said.
The company said it will report the outcome of the first 600
patients in the clinical trial by the end of May.
It added that the clinical trial will also be done in the
UK, China, France, Germany, Hong Kong, Italy, Japan Korea, the Netherlands,
Singapore, Spain, Sweden, Switzerland and Taiwan.
Pfizer, an American biopharmaceutical company, on Tuesday,
said its COVID-19 vaccine could be ready for emergency use by September.
The World Health Organisation (WHO) said there are about 20
different potential COVID-19 vaccines currently being developed.
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com